Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AIDS Drug Rebates Were “Largest Driver” Of ADAP Budget Growth In 2007

Executive Summary

Manufacturer rebates on AIDS drugs now account for 18 percent of the overall budget for AIDS Drug Assistance Programs, compared to 6 percent in the mid-1990s, according to the National ADAP Monitoring Project's annual report, released April 8

You may also be interested in...



Merck’s Isentress – Is $27/Day A High Price To Pay For HIV Treatment?

Merck's first-in-class integrase inhibitor Isentress marks the firm's return to the HIV market, but also to the intense pricing scrutiny that surrounds AIDS products

Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel